115 related articles for article (PubMed ID: 7887242)
1. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
Porter JB; Singh S; Hoyes KP; Epemolu O; Abeysinghe RD; Hider RC
Adv Exp Med Biol; 1994; 356():361-70. PubMed ID: 7887242
[No Abstract] [Full Text] [Related]
2. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Kontoghiorghes GJ; Kolnagou A
Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
[No Abstract] [Full Text] [Related]
3. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
Porter JB; Abeysinghe RD; Hoyes KP; Barra C; Huehns ER; Brooks PN; Blackwell MP; Araneta M; Brittenham G; Singh S
Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385
[TBL] [Abstract][Full Text] [Related]
4. Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
Richardson DR
Lancet; 2002 Aug; 360(9332):501-2. PubMed ID: 12241649
[No Abstract] [Full Text] [Related]
5. Long-term trials of deferiprone in Cooley's anemia.
Olivieri NF; Brittenham GM
Ann N Y Acad Sci; 1998 Jun; 850():217-22. PubMed ID: 9668542
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
8. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Fischer R; Engelhardt R
Lancet; 2003 Jan; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
[No Abstract] [Full Text] [Related]
9. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Brittenham GM; Nathan DG; Olivieri NF; Pippard MJ; Weatherall DJ
Lancet; 2003 Jan; 361(9352):183; author reply 183-4. PubMed ID: 12531619
[No Abstract] [Full Text] [Related]
10. An orally active iron chelator.
Nathan DG
N Engl J Med; 1995 Apr; 332(14):953-4. PubMed ID: 7877655
[No Abstract] [Full Text] [Related]
11. Do we need more iron-chelating drugs?
Kontoghiorghes GJ
Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
[No Abstract] [Full Text] [Related]
12. Long term deferiprone chelation therapy.
Hoffbrand VA; Wonke B
Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
[No Abstract] [Full Text] [Related]
13. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.
Epemolu OR; Singh S; Hider RC; Damani LA
Drug Metab Dispos; 1992; 20(5):736-41. PubMed ID: 1358580
[TBL] [Abstract][Full Text] [Related]
15. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
Kolnagou A; Kontoghiorghes GJ
Br J Haematol; 2010 Aug; 150(4):489-90; author reply 491. PubMed ID: 20507309
[No Abstract] [Full Text] [Related]
16. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
St Pierre TG
Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
[No Abstract] [Full Text] [Related]
17. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
Kidson-Gerber G; Lindeman R
Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
[No Abstract] [Full Text] [Related]
18. Protoporphyria induced by the orally active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one in C57BL/10ScSn mice.
Smith AG; Clothier B; Francis JE; Gibbs AH; De Matteis F; Hider RC
Blood; 1997 Feb; 89(3):1045-51. PubMed ID: 9028337
[TBL] [Abstract][Full Text] [Related]
19. Characterization of two isomeric beta-d-glucosiduronic acids derived from 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rat liver homogenate incubates.
Liu DY; Liu ZD; Piyamongkol S; Lu SL; Hider RC
J Pharm Pharmacol; 2002 Jul; 54(7):951-7. PubMed ID: 12162714
[TBL] [Abstract][Full Text] [Related]
20. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
